Aimmune Therapeutics, Inc. (NASDAQ:AIMT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

AIMT has been the topic of several other reports. Wedbush restated an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, July 24th. BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. ValuEngine upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Finally, Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.50.

Shares of Aimmune Therapeutics (AIMT) traded up 0.24% on Tuesday, hitting $21.00. 172,607 shares of the company’s stock were exchanged. The stock’s market cap is $1.06 billion. The company’s 50-day moving average price is $20.60 and its 200 day moving average price is $20.06. Aimmune Therapeutics has a 12-month low of $14.01 and a 12-month high of $27.31.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.01. On average, equities analysts predict that Aimmune Therapeutics will post ($2.71) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Aimmune Therapeutics, Inc. (AIMT) Upgraded to “Hold” at Zacks Investment Research” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-upgraded-to-hold-at-zacks-investment-research/1530325.html.

In other Aimmune Therapeutics news, insider Stephen George Dilly sold 50,000 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $21.46, for a total transaction of $1,073,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Susan E. Barrowcliffe sold 6,110 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total transaction of $134,420.00. Following the sale, the insider now owns 960 shares in the company, valued at $21,120. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 188,470 shares of company stock worth $3,942,092. 24.56% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its stake in shares of Aimmune Therapeutics by 10.1% in the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after buying an additional 499 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock worth $130,000 after buying an additional 4,900 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Aimmune Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC raised its stake in shares of Aimmune Therapeutics by 31.2% in the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after buying an additional 3,757 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Aimmune Therapeutics during the second quarter worth $333,000. Institutional investors and hedge funds own 72.90% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.